Hematology-OncologyctDNAFollicular lymphoma
Baseline Circulating Tumor DNA as a Prognostic Biomarker in Untreated Follicular Lymphoma: Insights from the GALLIUM Trial
By MedXY|Apr 27, 2026
Baseline ctDNA levels predict early progression and poor survival in untreated follicular lymphoma, outperforming traditional risk scores like FLIPI. This study highlights ctDNA’s potential as a stratification tool in clinical trials.